Sarah A. Holstein, MD, PhD | Department ...

Dr. Sarah Holstein

Claim this profile

University of Nebraska Medical Center

Studies Multiple Myeloma
Studies Immune Dysfunction
9 reported clinical trials
17 drugs studied

Area of expertise

1Multiple Myeloma
Sarah Holstein has run 8 trials for Multiple Myeloma. Some of their research focus areas include:
Stage III
Stage IV
2Immune Dysfunction
Sarah Holstein has run 1 trial for Immune Dysfunction.

Affiliated Hospitals

Image of trial facility.
University Of Nebraska Medical Center
Image of trial facility.
Nebraska Medicine-Village Pointe

Clinical Trials Sarah Holstein is currently running

Image of trial facility.

Iberdomide

for Multiple Myeloma

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Recruiting1 award Phase 210 criteria
Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria

More about Sarah Holstein

Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Sarah Holstein has experience with
  • Dexamethasone
  • Daratumumab
  • Lenalidomide
  • Iberdomide
  • Ixazomib
  • CYNK-001

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sarah Holstein specialize in?
Is Sarah Holstein currently recruiting for clinical trials?
Are there any treatments that Sarah Holstein has studied deeply?
What is the best way to schedule an appointment with Sarah Holstein?
What is the office address of Sarah Holstein?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security